Biogen Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;'>BII</div>
BIIB -- USA Stock  

USD 241.75  0.76  0.31%

Astrazeneca PLC would recover faster from the latest slide as its shares price went up 0.48% to Biogen's 0.61%As many rational traders are trying to avoid healthcare space, it makes sense to go over Biogen Inc a little further and understand how it stands against Astrazeneca PLC and other similar entities. We are going to analyze some of the competitive aspects of both Biogen and Astrazeneca.
Published over a month ago
View all stories for Biogen | View All Stories
Is Astrazeneca more volatile than Biogen Inc (NASDAQ:BIIB)?
By analyzing existing technical and fundamental indicators between Biogen and Astrazeneca, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Astrazeneca with a short position in Biogen. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biogen has an asset utilization ratio of 63.34 percent. This suggests that the company is making $0.63 for each dollar of assets. An increasing asset utilization means that Biogen Inc is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Biogen or Astrazeneca is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Biogen's Liquidity

Biogen financial leverage refers to using borrowed capital as a funding source to finance Biogen Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biogen financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biogen's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Biogen, but it might be worth checking our own buy vs. sell analysis

Correlation Between Biogen and Astrazeneca PLC

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Biogen together with similar or unrelated positions with a negative correlation. For example, you can also add Astrazeneca PLC to your portfolio. If Astrazeneca PLC is not perfectly correlated to Biogen it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Biogen for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between BIIB and AZN for more information.

Sale by Alfred Sandrock of 1500 shares of Biogen

Legal trades by Biogen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biogen insider trading alert for sale of common stock by Alfred Sandrock, EVP Research & Development, on 6th of November 2020. This event was filed by Biogen Inc with SEC on 2020-11-06. Statement of changes in beneficial ownership - SEC Form 4. Alfred Sandrock currently serves as group senior vice president chief medical officer of Biogen Inc [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Biogen Investor Appetite?

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now check Biogen revenue. Based on the latest financial disclosure, Biogen Inc reported 14.49 B of revenue. This is 89.99% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers?General industry. The revenue for all United States stocks is 53.58% lower than that of Biogen. As for Astrazeneca PLC we see revenue of 25.7 B, which is much higher than that of the Drug Manufacturers?General

Biogen14.49 Billion
Sector0.0
Astrazeneca25.7 Billion
14.5 B
Biogen
Sector
25.7 B
Astrazeneca

Biogen has 85 percent chance to stay above $272 in 2 months

Current total risk alpha is at -0.13. Biogen Inc has relatively low volatility with skewness of 1.82 and kurtosis of 7.88. However, we advise all investors to independently investigate Biogen Inc to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Whereas some other companies in the drug manufacturers?general industry are either recovering or due for a correction, Biogen may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 20th of October 2020, we see that Biogen follows the market closely. The company is undervalued with below average odds of financial turmoil within the next 24 months. Our overall 30 days 'Buy-Sell' recommendation on the company is Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Biogen Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com